Gapping up
In reaction to earnings/guidance:
- NKE +13.1%, KMX +5.5%, APOG +4.1%
Other news:
- OSMT +47.2% (announces Alora will acquire Osmotica's portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 mln)
- PIRS +21.7% (announces inhaled CTGF inhibitor PRS-220 for idiopathic pulmonary fibrosis and 17 million dollar grant from bavarian government to accelerate program development for post-COVID-19 pulmonary fibrosis)
- SPCE +12.3% (receives Full Commercial Launch License from FAA)
- BVS +5.3% (completes minority investment in Vaporox)
- ASAN +2.7% (TWLO and ASAN to dual list on Long-Term Stock Exchange in August, according to WSJ)
- LPRO +2.7% (signs producer agreement with insurance carriers)
- GVA +2.5% (wins $16 mln Alaska airport contract)
- IQV +2.2% (introduces Clinical Data Analytics Suite)
- TIGR +2.2% (UP Fintech's Tiger Brokers (Singapore) Pte received approval-in-principle to be admitted as a Clearing Member of The Central Depository)
- ONCS +2% (CEO resigns)
- BTG +1.6% (commences arbitration proceedings for Menankoto permit)
- MRTX +1.6% (receives FDA Breakthrough Therapy Designation for adagrasib)
- DLX +1.6% (announces collaboration with MSFT to bring its HR and payroll solutions to Dynamics 365)
- HEAR +1.1% (partnering with NBA star Immanuel Quickley)
Analyst comments:
- GMS +4.2% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- LAZR +3.5% (upgraded to Outperform from Neutral at Robert W. Baird)
- VMC +2.9% (upgraded to Buy from Hold at Jefferies)
- NOK +2.7% (upgraded to Buy from Neutral at Goldman)
- NTAP +2.2% (upgraded to Outperform from Mkt Perform at Raymond James)
- CRH +2% (upgraded to Buy from Hold at Berenberg)
- CLR +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- MLM +1.7% (upgraded to Buy from Hold at Jefferies)
- NFLX +1.4% (upgraded to Outperform from Neutral at Credit Suisse)
- SPLK +1.4% (upgraded to Buy from Sell at Arete)
- DAR +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- DRI +1.1% (upgraded to Buy from Neutral at MKM Partners)